SBH
NVO

Segall Bryant & Hamill’s Novo Nordisk NVO Stock Holding History

Segall Bryant & Hamill’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-83,980
Closed -$5.83M – 614
2025
Q1 		$5.83M Sell
83,980
-15,203
-15% -$1.26M 0.09% 290
2024
Q4 		$8.53M Sell
99,183
-219,357
-69% -$23.7M 0.12% 251
2024
Q3 		$37.9M Buy
318,540
+93,922
+42% +$12.5M 0.52% 45
2024
Q2 		$32.1M Sell
224,618
-22,735
-9% -$3.01M 0.57% 41
2024
Q1 		$31.8M Sell
247,353
-2,366
-0.9% -$282K 0.6% 43
2023
Q4 		$25.8M Sell
249,719
-364,070
-59% -$36M 0.5% 63
2023
Q3 		$55.8M Sell
613,789
-49,259
-7% -$4.34M 0.65% 32
2023
Q2 		$53.7M Buy
663,048
+10,368
+2% +$847K 0.56% 43
2023
Q1 		$51.9M Buy
652,680
+49,568
+8% +$3.51M 0.56% 44
2022
Q4 		$40.8M Buy
603,112
+85,320
+16% +$5M 0.46% 62
2022
Q3 		$25.7M Buy
517,792
+512,142
+9,064% +$27.4M 0.31% 96
2022
Q2 		$315K Hold
5,650
– – ﹤0.01% 657
2022
Q1 		$314K Buy
+5,650
New +$290K ﹤0.01% 671
2021
Q4 		– Sell
-5,810
Closed -$278K – 694
2021
Q3 		$278K Buy
5,810
+560
+11% +$27.1K ﹤0.01% 710
2021
Q2 		$220K Buy
+5,250
New +$204K ﹤0.01% 733

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Segall Bryant & Hamill's NVO Position: Q2 2025 in Review

Segall Bryant & Hamill sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 83,980 shares — an estimated $5.83M sold.

Segall Bryant & Hamill first reported a position in NVO in Q2 2021 and held it in 15 quarters. The position peaked at $55.8M in Q3 2023. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Segall Bryant & Hamill reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 83,980 Novo Nordisk shares in Q2 2025, an estimated $5.83M.
  • Segall Bryant & Hamill first reported a position in Novo Nordisk in Q2 2021 and held it in 15 quarters.
  • Segall Bryant & Hamill's Novo Nordisk position peaked at $55.8M in Q3 2023.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Segall Bryant & Hamill's 13F filing for Q2 2025, filed 12 Aug 2025.